๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

The application of a numerical scoring system for evaluating the histological outcome in patients with chronic hepatitis B followed in long term

โœ Scribed by Gudrun Lindh; Ola Weiland; Hans Glaumann


Publisher
John Wiley and Sons
Year
1988
Tongue
English
Weight
645 KB
Volume
8
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

โœฆ Synopsis


A numerical scoring system was applied and compared with conventional histological classification to assess the histological outcome in 42 patients with chronic hepatitis B followed for 16 to 162 months (mean = 75 months). Four histological categories in the biopsies were assessed and scored: (i) piecemeal necrosis; (ii) lobular necrosis; (iii) portal inflammation, and (iv) fibrosis and cirrhosis. The sum of all four categories was defined as the "Histological Activity Index." Altogether, 102 liver specimens, including 2 to 4 repeats from each patient, were investigated. A good correlation was noted between a high value of the Histological Activity Index score and several liver histology as monitored by conventional terminology for chronic hepatitis. Among patients with HBeAg persistence, 8 of 14 (57%) deteriorated during follow-up as judged by an increase in the Histological Activity Index score compared to 3 of 13 (23%) of the patients with HBeAg seroconversion (0.5 < p < 0.1). Piecemeal necrosis has been postulated to be a predictive marker for the eventual development of cirrhosis. Here, we found that a low score for piecemeal necrosis in the initial liver biopsy was significantly less predictive of a high fibrosis score in the follow-up biopsy than was a high score for initial piecemeal necrosis (p < 0.001).

It is concluded that the scoring system used can be applied to monitor the histological long-term follow-up, especially when separated into its four constituent categories. It also offers a means of predicting a chronic hepatitis outcome.

Disease activity and thus histological changes may fluctuate during the course of chronic hepatitis B infection. The exacerbations may be due to clearance of HBeAg, to superinfection with hepatitis A, non-A, non-B or hepatitis D virus (HDV) (delta agent), or to changes in immune reactivity (spontaneous or due to immunosuppressive treatment) in the host (1-4). Among the hepatotropic viruses, HDV seems to be the most impor-


๐Ÿ“œ SIMILAR VOLUMES


Long-term entecavir therapy results in t
โœ Ting-Tsung Chang; Yun-Fan Liaw; Shun-Sheng Wu; Eugene Schiff; Kwang-Hyub Han; Ch ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 679 KB

One year of treatment with entecavir (0.5 mg daily) in nucleoside-naive patients with hepatitis B e antigen (HBeAg)-positive or HBeAg-negative chronic hepatitis B (CHB) resulted in significantly improved liver histology and virological and biochemical endpoints in comparison with lamivudine. Patient